Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloNK plus rituximab in relapsing B-cell-dependent rheumatologic diseases
2025-520461-41-00Phase 2Suspended
- Sponsor
- Artiva Biotherapeutics, Inc.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of zabalafin and rituximab in rheumatoid arthritis (RA), Sjögren's syndrome, systemic sclerosis (SSc) and 1 more, sponsored by Artiva Biotherapeutics, Inc. Primary endpoints: Dose-limiting toxicities and maximum tolerated/administrated dose, Idiopathic inflammatory myopathies efficacy at Week 52 and 3 more. Started Oct 2025; status: suspended.
02
Drugs
zabalafinrituximab
03
Conditions
rheumatoid arthritis (RA)Sjögren's syndromesystemic sclerosis (SSc)Autoimmune Myopathies
Beyond the preview
Go deeper on 2025-520461-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520461-41-00.